A
Amit M. Oza
Researcher at Princess Margaret Cancer Centre
Publications - 542
Citations - 25057
Amit M. Oza is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Ovarian cancer & Cancer. The author has an hindex of 65, co-authored 485 publications receiving 19164 citations. Previous affiliations of Amit M. Oza include University Health Network & Ontario Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
517O Overall survival (OS) at 7-year (y) follow-up (f/u) in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) who received maintenance olaparib in the SOLO1/GOG-3004 trial
Paul DiSilvestro,Sushmita Banerjee,N. Colombo,Giovanni Scambia,B-G. Kim,Ana Oaknin,Michael Friedlander,Alla Lisyanskaya,Anne Floquet,A. Leary,GS Sonke,Charlie Gourley,Amit M. Oza,Antonio Gonzalez Martin,Carol Aghajanian,W. Bradley,Cara Mathews,Jeremiah E Mcnamara,E. Lowe,Kathleen N. Moore +19 more
TL;DR: In the Phase III SOLO1/GOG-3004 trial (NCT01844986), maintenance olaparib provided sustained benefit beyond the end of treatment in pts with newly diagnosed advanced OC and a BRCAm as mentioned in this paper .
Journal ArticleDOI
Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
David M. O'Malley,Amit M. Oza,Domenica Lorusso,Carol Aghajanian,Ana Oaknin,Andrew Dean,Nicoletta Colombo,Johanne I Weberpals,Andrew R Clamp,Giovanni Scambia,Alexandra Leary,Robert G. Holloway,Margarita Amenedo Gancedo,Peter C.C. Fong,Jeffrey C. Goh,Elizabeth M. Swisher,Lara Maloney,Sandra Goble,Kevin K. Lin,Tanya Todorova Kwan,Jonathan A. Ledermann,Robert E. Coleman +21 more
TL;DR: The ARIEL3 trial as mentioned in this paper showed that rucaparib treatment was associated with exceptional benefit compared with placebo: 79/375 (21.1%) vs 4/189 (2.1%), respectively (p < 0.0001).
Journal ArticleDOI
A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: A trial of the PMH Phase II Consortium
Stephen Welch,Helen Mackay,H. Hirte,Gini F. Fleming,Rebecca L. Morgan,Lisa Wang,C. Blattler,S. P. Ivy,Amit M. Oza +8 more
TL;DR: A two-stage open-label phase II study in advanced EC with sunitinib, an oral tyrosine kinase inhibitor of multiple VEGF receptors shows preliminary activity in EC, and this trial will proceed to a second stage of accrual to further explore the efficacy and safety of sunit inib.
Proceedings ArticleDOI
Abstract CT012: Open-label, multicenter, Phase Ib study to assess safety, tolerability and efficacy of adavosertib monotherapy in patients with advanced solid tumors: Expansion cohorts
Todd M. Bauer,Kathleen N. Moore,Janet S. Rader,Fiona Simpkins,Alain C. Mita,J. Thaddeus Beck,Lowell L. Hart,Quincy Chu,Amit M. Oza,Anna V. Tinker,Karen So,Esteban Rodrigo Imedio,Sanjeev Kumar,Ganesh Mugundu,Suzanne Jenkins,Juliann Chmielecki,Suzanne F. Jones,David R. Spigel,Siqing Fu +18 more
TL;DR: Adavosertib was generally well tolerated and showed preliminary antitumor activity, particularly in BRCAwt as well as PARPi-failure BRCAm OC pts and DCR was modest across all patient cohorts.
Journal ArticleDOI
Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.
Cara Mathews,Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byoung-Gie Kim,Ana Oaknin,Michael Friedlander,Alla Sergeevna Lisyanskaya,Anne Floquet,Alexandra Leary,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martín,Carol Aghajanian,William H. Bradley,Elizabeth S. Lowe,Ralph Bloomfield,Paul DiSilvestro +19 more
TL;DR: In SOLO1 (NCT01844986), maintenance olaparib significantly improved progression-free survival (PFS) vs placebo vs placebo and in pts wit...